still down

maybe DKSH, BONIA, AEON

yeap but do not move.

any people have view on sam engineering

yes.

WILL MOVE HIGHER.

1.80

GTRONIC - Corporate in the move. Something is going on

luckily already buy enough. but will buy more if below 2.25

dksh is 2.54

buy gtronic

today up 2.38

my cost is lower than the 0.39 for ytlpower-wb

14.12

some fund want to clear the stock before year end.

ytlpower wb

some one is buying

all the goverment hospital is using DKSH.

will only enter when is below 1.50

will buy more if drop to 1.05

normal lah.

look like somthing is in aeon. Maybe will trade higher than current price. maybe 30x

The investment goods segments are projected to
outgrow the consumer segments in the next five years,
as emerging nations seek to grow their industrial base and exploit the gains of their improved
technical prowess. In addition, emerging markets are investing heavily in infrastructure, such
as roads, energy and water supplies, and schools. This creates the need for new technological
and chemical components, many of which will be supplied by companies from outside the
country as local industries struggle to keep pace, and are often not able to provide the
required equipment and materials at all.

Each week new economic and corporate data appear to confirm an inescapable truth:
Companies in the West are having to work harder to grow, increase revenues and cut costs
as the global economy struggles to recover.
In Europe and the US, where consumer spending growth is fragile, companies
are increasingly seeking to enhance effectiveness and improve the bottom line by
outsourcing activities not within their core competencies.
Meanwhile halfway across the globe, in Asia, a different story is unfolding as new
consumer groups and opportunities are emerging.
The trend is particularly strong in South East Asia, one of the fastest growing
regions. In countries such as Thailand, Malaysia or Vietnam, the middle class is
expanding so rapidly that Asia Pacific’s share of global consumption is expected
to almost double within the next decade. By 2020, the region is projected to
account for more than 40% of world consumption – more than that of Europe
and the US combined. In fact, Asia Pacific has already overtaken North America
in terms of inter-regional trade and has evolved into an industrial production
powerhouse. In addition, Asia’s importance as a sales and sourcing market is
continuously growing.

DKSH and SGS extend auditing and certification partnership for another three years













07.12.2012 | DKSH, the leading Market Expansion Services provider with a focus on Asia, extends its system and services certification partnership with SGS, the world’s leading inspection, verification, testing and certification company, for the audit and certification of 20 sites in more than ten countries.






Zurich, Switzerland, December 7, 2012 – DKSH Business Unit Healthcare, the leading outsourcing services partner for healthcare companies in Asia, provides a wide range of commercial services to over 150 multinational pharmaceutical, medical devices, Over-The-Counter (OTC) and consumer health companies across Asia.

One of the cornerstones of the unique services capability mix of DKSH across all healthcare channels is its strong focus on quality and compliance. To sustain our excellent service levels, DKSH is extending the existing partnership with SGS for another three years. Under the agreement, SGS will validate and certify the 20 dedicated healthcare quality management systems in more than ten countries across Asia according to ISO 9001:2008, ISO 13485, Good Manufacturing (GMP) as well as Good Distribution Practice (GDP) standards.

The growing complexity of the healthcare value chain, the widely scattered healthcare outlets, as well as climate and infrastructural challenges in emerging markets across Asia, demand highest levels of quality and compliance from service providers. These certifications are global standards and proven indicators, and provide the assurance for high-quality and compliant services in the healthcare industry.

SGS has been certifying DKSH’s logistics and distribution infrastructure and capabilities for over ten years, including the ISO 9001:2008 and ISO 13485 certifications of all dedicated healthcare distribution centers across Asia. Most recent certifications obtained were the ISO 13485 in Singapore and Korea as well as GDP in Malaysia.

"We are very pleased that DKSH Healthcare is extending the close partnership with SGS across the region. DKSH has set the benchmark for quality and compliance in the Market Expansion Services industry in Asia and we look forward to further auditing and certifying their services," says François Marti, Executive Vice President for Systems & Services Certification, SGS.

Charles Toomey, Head Business Unit Healthcare, DKSH, adds: "Our close partnership with SGS enables us to stay ahead of the game by not only complying with global quality standards and requirements but also by strengthening our leadership position in quality and compliance in the healthcare services outsourcing industry across Asia. The extension of our partnership with SGS will support us in further enhancing the quality of our Market Expansion Services for all of our clients and customers.


About DKSH

DKSH is the leading Market Expansion Services Group with a focus on Asia. As the term "Market Expansion Services" suggests, DKSH helps other companies and brands to grow their business in new or existing markets.

Publicly listed on the SIX Swiss Exchange since March 2012, DKSH is a global company headquartered in Zurich, with 650 business locations in 35 countries – 630 of them in Asia, and 26,000 specialized staff. In 2011, DKSH generated net sales of CHF 7.3 billion.

DKSH Business Unit Healthcare is the leading Market Expansion Services provider for healthcare companies seeking to grow their business in Asia, offering a wide range of solutions that extend from product feasibility studies and registration to importation, customs clearance, marketing and sales, to physical distribution, invoicing and cash collection. Products available through DKSH Healthcare include ethical pharmaceuticals, consumer health, over-the-counter (OTC), as well as medical devices.

With 150 business locations in 13 countries and over 8,000 specialized staff, Business Unit Healthcare serves over 160,000 customers and generated net sales of around CHF 2.9 billion in 2011.


About SGS

SGS is the world’s leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 70,000 employees, SGS operates a network of over 1,350 offices and laboratories around the world.

if cpo drop to below 1500.00 than will be back for ppb group and wilmar itself.

look like the game maybe near end

Is Aeon Co. (M) Bhd. a Good Long-Term Investment? Still keep my AEON.

see at 1.50

buy at your own risk.

one day will like transmile. operation issue and human issue. lack of action and just talking only.

DKSH
IGB
PHARMA

why not just say 2.00. not interested

if equity canoot play than property even worse.

look like is the past already

look like down. now is 8.18

is stable.

pharma is up

for investment in share shall have at least 15% to 25% minimum. as long as not loss than is good enough.

1.50 level with be good for entry.

STILL DOWN. NO WAY TO UP FURTHER.

TP is 9.17. but do nto when to reach

normal up and down. but something is going at AEON for 12 months

the e-mail which i receive is just ask the subscriber to buy the icap share in order to have voting rights.

hopefully can reach 3.++

Aeon price up or down.

3Q12 margin surge on better product mix
9M12 core net profit rises 17% yoy - inline
Globe reported a stronger 9M12 net profit of RM30.1m (+39% yoy) although
partially contributed by a RM4.2m gain on disposal of its Jitra plant. Adjusted for
the EI, 9M12 core net profit growth of +16.7% yoy to RM25.2m was equally
impressive and underpinned primarily by margin expansion. 9M12 EBITDA
margin improved to 32.5% from 25.4% for 9M11 on the back of cost discipline as
well as a shift in product mix towards higher margin products. A key contributor
to this is the maiden contribution from its proximity sensors that achieved mass
production in July 2012. Better economies of scale from its wafer processing job
and quartz crystal timing devices are also likely to have aided margin
enhancement.
The successful execution of its proximity sensor product is another testimony of
Globe’s dynamic management team ability to identify new business opportunities
and penetrate new market segments. We continue to like the stock for its strong
earnings growth prospects (3-year CAGR of 22.7% over FY11-FY14) and its
highly attractive dividend yield (9.5% for FY13).

If pandin drop to 1.80 level than i safe to enter. unless the sale simprove and the economy outlook is improve.

when ge announced than willd rop lower again

If the accq really true than the sales will increase 50% and thus the share price.